1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial

• DOI: 10.1016/j.annonc.2023.09.739
• Publication Date: 2023-10-20T11:38:52Z
• Authors: M.M. Awad; P.M. Forde; N. Girard; J.D. Spicer; C. Wang; S. Lu; T. Mitsudomi; E. Felip; S. Broderick; S.J. Swanson; J.R. Brahmer; K.M. Kerr; G. Saylors; K-N. Chen; J.L. Cai; J. Mahmood; J. Neely; D. Balli; N. Hu; M. Provencio Pulla